Mattel Children's Hospital, UCLA
Los Angeles, California, United States
Hospital in Los Angeles, California
757 Westwood Plaza, Los Angeles, CA 90095
About Mattel Children's Hospital, UCLA
"Visit the UCLA Health website for coronavirus updates."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Children's Oncology Group
36
National Institute of Allergy and Infectious Diseases (NIAID)
33
National Cancer Institute (NCI)
25
University of California, Los Angeles
7
Boston Children's Hospital
3
David Williams
3
Novartis Pharmaceuticals
3
Children's Hospital Los Angeles
2
Children's Hospital Medical Center, Cincinnati
2
Marinus Pharmaceuticals
2
Nationwide Children's Hospital
2
Clinical Trials at Mattel Children's Hospital, UCLA
During the past decade, Mattel Children's Hospital, UCLA conducted 59 clinical trials. In the 10-year time frame, 59 clinical trials started and 31 clinical trials were completed, i.e. on
average, 52.5% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 16 clinical trials were completed. i.e. 94.1%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children
1996-09-01
Completed
819
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
1995-11-01
Completed
85
A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment
Completed
750
An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex
Completed
660
A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine
1993-04-01
Completed
250
A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection
1996-09-01
Completed
400
A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
2007-08-01
Completed
1,600
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Mattel Children's Hospital, UCLA" #1 sponsor was "Children's Oncology Group" with 36 trials, followed by "National Institute of Allergy and Infectious Diseases (NIAID)" with 33 trials
sponsored, "National Cancer Institute (NCI)" with 25 trials sponsored, "University of California, Los Angeles" with 7 trials sponsored and "Boston Children's Hospital"
with 7 trials sponsored. Other sponsors include 44 different institutions and
companies that sponsored additional 41 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Mattel Children's Hospital, UCLA"
#1 collaborator was "National Cancer Institute (NCI)" with 37 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 15 trials as a collaborator, "Glaxo Wellcome" with 6 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator and "Children's Oncology Group" with 4 trials as a collaborator. Other collaborators include 75 different institutions and companies that were
collaborators in the rest 62 trials.
Clinical Trials Conditions at Mattel Children's Hospital, UCLA
According to Clinical.Site data, the most researched conditions in "Mattel Children's Hospital, UCLA" are
"HIV Infections" (35 trials), "Pregnancy" (10 trials), "Recurrent Osteosarcoma" (10 trials), "Recurrent Neuroblastoma" (9 trials) and "Refractory Neuroblastoma" (9 trials). Many other conditions were trialed in "Mattel Children's Hospital, UCLA" in a lesser frequency.
Clinical Trials Intervention Types at Mattel Children's Hospital, UCLA
Most popular intervention types in "Mattel Children's Hospital, UCLA" are "Drug" (102 trials), "Other" (50 trials), "Biological" (26 trials), "Procedure" (23 trials) and "Radiation" (19 trials). Other intervention types were less common.
The name of intervention was led by "Laboratory Biomarker Analysis" (23 trials), "Cyclophosphamide" (19 trials), "Vincristine Sulfate" (18 trials), "Zidovudine" (17 trials) and "Radiation Therapy" (14 trials). Other intervention names were less common.
Clinical Trials Genders at Mattel Children's Hospital, UCLA
The vast majority of trials in "Mattel Children's Hospital, UCLA" are
137 trials for "All" genders, 9 trials for "Male" genders and 7 trials for "Female" genders.
Clinical Trials Status at Mattel Children's Hospital, UCLA
Currently, there are NaN active trials in "Mattel Children's Hospital, UCLA".
undefined are not yet recruiting,
34 are recruiting,
29 are Active, not recruiting,
and 2 are Enrolling by invitation.
In total, there were 75 completed trials in Mattel Children's Hospital, UCLA,
2 suspended trials,
and 5 terminated clinical trials to date.
Out of the total trials that were conducted in Mattel Children's Hospital, UCLA, 18 "Phase 1"
clinical trials were conducted, 50 "Phase 2" clinical
trials and 42 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 3 trials, and there were
also 12 trials that are defined as “Not Applicable".